Cargando…

Cost Reduction of Inhaled Tobramycin by Use of Preservative-Free Intravenous Tobramycin Given via Inhalation

This study evaluates drug cost outcomes related to automatic therapeutic substitution of branded tobramycin solution for inhalation (TOBI(®)) with inhaled generic preservative-free intravenous tobramycin (PFIT). A retrospective single-center evaluation of inhaled tobramycin use from 2008 through 201...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gauthier, Timothy P., Wasko, Justin, Unger, Nathan R., Abbo, Lilian M., Fernandez, Margaret, Aragon, Laura
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4810404/ https://www.ncbi.nlm.nih.gov/pubmed/27025517 http://dx.doi.org/10.3390/antibiotics5010002

Ejemplares similares

Efficacy of inhaled tobramycin in severe nosocomial pneumonia
por: Kuzovlev, A, et al.
Publicado: (2012)

Inhaled tobramycin for the treatment of nosocomial pneumonia in sepsis
por: Kuzovlev, A, et al.
Publicado: (2014)

Adherence with tobramycin inhaled solution and health care utilization
por: Briesacher, Becky A, et al.
Publicado: (2011)

Evidence of Inhaled Tobramycin in Non-Cystic Fibrosis Bronchiectasis
por: Vendrell, Montserrat, et al.
Publicado: (2015)

Early preventive administration of inhaled tobramycin in severe polytrauma
por: Kuzovlev, A, et al.
Publicado: (2015)

Population Pharmacokinetics of Inhaled Tobramycin Powder in Cystic Fibrosis Patients
por: Ting, L, et al.
Publicado: (2014)

Treatment satisfaction in cystic fibrosis: early patient experience with tobramycin inhalation powder
por: Greenberg, Jonathan, et al.
Publicado: (2016)

Eradication of Pseudomonas aeruginosa in cystic fibrosis patients with inhalation of dry powder tobramycin
por: Akkerman-Nijland, Anne M., et al.
Publicado: (2020)

Systematic review of the dry powder inhalers colistimethate sodium and tobramycin in cystic fibrosis
por: Uttley, Lesley, et al.
Publicado: (2013)

Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis
por: MacLeod, David L., et al.
Publicado: (2009)

Exacerbation of chronic renal failure because of inhaled tobramycin in a lung transplant patient
por: Mora Cuesta, Víctor M., et al.
Publicado: (2022)

Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection
por: Greenwood, James, et al.
Publicado: (2017)

Adherence to tobramycin inhaled powder vs inhaled solution in patients with cystic fibrosis: analysis of US insurance claims data
por: Hamed, Kamal, et al.
Publicado: (2017)

Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin Free Base in Non-Cystic Fibrosis Bronchiectasis Patients
por: Hoppentocht, Marcel, et al.
Publicado: (2016)

Comparing inhaled colistin with inhaled fosfomycin/tobramycin as an adjunctive treatment for ventilator‐associated pneumonia: An open‐label randomized controlled trial
por: Hakamifard, Atousa, et al.
Publicado: (2023)

Pharmacokinetics of intravenous and inhaled salbutamol and tobramycin: An exploratory study to investigate the potential of exhaled breath condensate as a matrix for pharmacokinetic analysis
por: Kruizinga, Matthijs D., et al.
Publicado: (2020)

Home videos of cystic fibrosis patients using tobramycin inhalation powder: Relation of flow and cough
por: Meerburg, Jennifer J., et al.
Publicado: (2019)

Is it Worth Adding Systemic Antibiotics to Inhalational Tobramycin Therapy to Treat Pseudomonas Infections in Cystic Fibrosis?
por: Karki, Kumar, et al.
Publicado: (2021)

Eradication of Burkholderia cepacia complex in cystic fibrosis patients with inhalation of amiloride and tobramycin combined with oral cotrimoxazole
por: Akkerman-Nijland, Anne M., et al.
Publicado: (2023)

Tobramycin Inhalation Powder (TIP): An Efficient Treatment Strategy for the Management of Chronic Pseudomonas Aeruginosa Infection in Cystic Fibrosis
por: Lam, John, et al.
Publicado: (2013)

Economic Evaluation of Tobramycin Inhalation Powder for the Treatment of Chronic Pulmonary Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis
por: Panguluri, Srilekha, et al.
Publicado: (2017)

Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial
por: Nichols, David P, et al.
Publicado: (2022)

In Vitro Synergy of Cefamandole-Tobramycin Combinations
por: Valenti, August J., et al.
Publicado: (1977)

Tobramycin Nanoantibiotics and Their Advantages: A Minireview
por: Rosalia, Mariella, et al.
Publicado: (2022)

Free and Nanoencapsulated Tobramycin: Effects on Planktonic and Biofilm Forms of Pseudomonas
por: Sans-Serramitjana, Eulalia, et al.
Publicado: (2017)

Inhaled tobramycin solution-associated recurrent eosinophilia and severe persistent bronchospasm in a patient with cystic fibrosis: a case report
por: Santos, Roberto P, et al.
Publicado: (2007)

Tobramycin inhalation powder for the treatment of pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis: a review based on clinical evidence
por: Hamed, Kamal, et al.
Publicado: (2017)

Unknown Renal Impairment: A Rare Case of Inhaled Tobramycin Induced Acute Kidney Injury in a Cystic Fibrosis Patient
por: Miller, Tyler, et al.
Publicado: (2021)

Effects of long-term tobramycin inhalation solution (TIS) once daily on exacerbation rate in patients with non-cystic fibrosis bronchiectasis
por: Terpstra, Lotte C., et al.
Publicado: (2022)

Impact of tobramycin on the performance of microbial fuel cell
por: Wu, Wenguo, et al.
Publicado: (2014)

Tobramycin and vestibulotoxicity: retrospective analysis of four cases
por: Vonk, S E M, et al.
Publicado: (2022)

Development of a novel tobramycin dependent riboswitch
por: Kraus, Leon, et al.
Publicado: (2023)

Effect of adjunctive tobramycin inhalation versus placebo on early clinical response in the treatment of ventilator-associated pneumonia: the VAPORISE randomized-controlled trial
por: Stokker, Jason, et al.
Publicado: (2020)

Antibacterial Efficacy of Liposomal Formulations Containing Tobramycin and N-Acetylcysteine against Tobramycin-Resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii
por: Alarfaj, Reem E., et al.
Publicado: (2022)

Assessing tobramycin levels and renal function following the implantation of CaSO(4) beads impregnated with tobramycin: A prospective cohort study
por: Alowais, Shuroug A., et al.
Publicado: (2022)

The ineffectiveness of tobramycin combination therapy in Streptococcus faecium endocarditis.
por: Goldstein, J. A., et al.
Publicado: (1983)

Diffusion Retardation by Binding of Tobramycin in an Alginate Biofilm Model
por: Cao, Bao, et al.
Publicado: (2016)

Differential Effects of Linkers on the Activity of Amphiphilic Tobramycin Antifungals
por: Fosso, Marina Y., et al.
Publicado: (2018)

Parallel Evolution of Tobramycin Resistance across Species and Environments
por: Scribner, Michelle R., et al.
Publicado: (2020)

Effect of Local Delivery of Vancomycin and Tobramycin on Bone Regeneration
por: Han, Wei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7psm6pmjs3ojk8ol3k028ibk5g